论文部分内容阅读
炎症性肠病(IBD)包括溃疡性结肠炎(UC)和克罗恩病(CD),5-氨基水杨酸(5-ASA)是IBD治疗中最经典的抗炎剂。IBD患者结直肠癌(CRC)的发病率较正常人群明显增高,长期使用5-ASA可减少IBD患者发生CRC的风险。5-ASA传统的抗炎机制是通过影响抑制前列腺素合成、调节各种细胞因子的产生而发挥抗炎作用的,新近研究发现5-ASA可能通过氧化物酶体增殖物激活受体(PPAR)-γ途径发挥抗炎和抗瘤作用。本文就5-ASA的作用新机制作一简要概述。
Inflammatory bowel disease (IBD) includes ulcerative colitis (UC) and Crohn’s disease (CD), and 5-aminosalicylic acid (5-ASA) is the most classic anti-inflammatory agent in IBD therapy. The incidence of colorectal cancer (CRC) in patients with IBD is significantly higher than that in the normal population, and the long-term use of 5-ASA reduces the risk of CRC in IBD patients. The traditional anti-inflammatory mechanism of 5-ASA exerts its anti-inflammatory effect by inhibiting the synthesis of prostaglandins and regulating the production of various cytokines. Recent studies have found that 5-ASA may exert anti-inflammatory effects through the activation of PPARs, -γ pathway to exert anti-inflammatory and anti-tumor effects. This article gives a brief overview of the new mechanism of 5-ASA.